Recon: FDA approves Protagonist and Takeda's drug for rare blood cancer

◆ ◆ The Wire takeaway

You now have regulatory validation to target polycythemia vera with a newly approved drug, opening access to a niche patient base with few existing treatments. This approval sets a new benchmark for rare blood disorder therapies you can leverage in market positioning.